We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Office of Management and Budget on Friday clarified President Trump’s new “one in, two out” regulations order, narrowing its scope to significant regulations with an economic impact of over $100 million per year — and said the release of new guidance documents would be considered on a case-by-case basis. Read More
The European Medicines Agency for the first time published data on its clinical data website from a withdrawn application, while adding clinical study reports for two generics. Read More
Japan’s largest drugmaker, Takeda Pharmaceuticals, said it will maintain its existing pricing model in the U.S., despite President Donald Trump’s call for drug companies to lower their prices. Read More
The European Parliament’s committee on Environment, Public Health and Food Safety voted Tuesday to approve a draft report that includes dozens of recommendations for improving how the EU promotes access to medicine and handles safety, intellectual property, and pricing issues. Read More
Leading drug firms and PhRMA have weighed in on the FDA’s plan to study the risks and benefits of online prescription drug communications and the possible impact of space limitations such as Twitter’s 140-character limit. Read More